BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

837 related articles for article (PubMed ID: 14529775)

  • 1. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
    Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control.
    Videtic GM; Fung K; Tomiak AT; Stitt LW; Dar AR; Truong PT; Yu EW; Vincent MD; Kocha WI
    Lung Cancer; 2001; 33(2-3):249-58. PubMed ID: 11551420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R; Shin DM; Glisson BS; Fossella FV; Murphy WK; Garden AS; Oswald MJ; Hong WK; Roth JA; Peters LJ
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):807-11. PubMed ID: 7860392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial.
    Blackstock AW; Bogart JA; Matthews C; Lovato JF; McCoy T; Livengood K; Ho C; White D; Atkins JN; Miller AA
    Clin Lung Cancer; 2005 Mar; 6(5):287-92. PubMed ID: 15845179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired diffusion capacity predicts for decreased treatment tolerance and survival in limited stage small cell lung cancer patients treated with concurrent chemoradiation.
    Videtic GM; Stitt LW; Ash RB; Truong PT; Dar AR; Yu EW; Whiston F
    Lung Cancer; 2004 Feb; 43(2):159-66. PubMed ID: 14739036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH; Bass D; Einhorn LH; Crawford J; Perez CA; Bartolucci A; Omura GA; Greco FA
    J Clin Oncol; 1993 Jul; 11(7):1223-9. PubMed ID: 8391064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: review of a single institution's experience.
    Ng M; Chong J; Milner A; MacManus M; Wheeler G; Wirth A; Michael M; Ganju V; McKendrick J; Ball D
    J Thorac Oncol; 2007 Jun; 2(6):506-13. PubMed ID: 17545845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
    Urtasun RC; Palmer M; Kinney B; Belch A; Hewitt J; Hanson J
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):337-42. PubMed ID: 9457818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).
    McClay EF; Bogart J; Herndon JE; Watson D; Evans L; Seagren SL; Green MR;
    Am J Clin Oncol; 2005 Feb; 28(1):81-90. PubMed ID: 15685040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
    Spiro SG; James LE; Rudd RM; Trask CW; Tobias JS; Snee M; Gilligan D; Murray PA; Ruiz de Elvira MC; O'Donnell KM; Gower NH; Harper PG; Hackshaw AK;
    J Clin Oncol; 2006 Aug; 24(24):3823-30. PubMed ID: 16921033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases.
    Shaw EG; Su JQ; Eagan RT; Jett JR; Maksymiuk AW; Deigert FA
    J Clin Oncol; 1994 Nov; 12(11):2327-32. PubMed ID: 7964948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer.
    Quon H; Shepherd FA; Payne DG; Coy P; Murray N; Feld R; Pater J; Sadura A; Zee B
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):39-45. PubMed ID: 9989512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
    Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL
    Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
    Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
    Glisson B; Scott C; Komaki R; Movsas B; Wagner H
    J Clin Oncol; 2000 Aug; 18(16):2990-5. PubMed ID: 10944132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.